[Treatment-resistant bacterial infection in specific bacterial species and developmental movement of new antibiotics--Mycobacterium].
Mycobacterium tuberculosis and atypical mycobacteriosis are potent diseases which had not been curable before. Progress of chemotherapy has a marked effect but not enough results. We are now waiting for the appearance of a new medicine. Other rifamycim derivatives are developed as antimycobacterial agents, which have a mainframe of 3'-hydroxy-5'-alkylpiperazinyl-benzoxazinorifamycins (KRMs). KRMs exceeds RFP in bacteriostatic function, and also have already established in vivo in chemotherapeutic efficacy. Another study will also reveal a higher of bactericidal function. We expect possibility of much more powerful and short-term initial chemotherapy.